rs28936701 — CYP1B1 R469W

CYP1B1 R469W — A Prevalent Cause of Inherited Congenital Glaucoma

The CYP1B1 gene encodes cytochrome P450 1B1¹¹ cytochrome P450 1B1
a monooxygenase enzyme involved in the oxidative metabolism of steroids, retinoids, polycyclic aromatic hydrocarbons, and other endogenous compounds. It is expressed broadly but is especially important in anterior eye segment tissues during fetal development. The Arg469Trp substitution at rs28936701 is one of the most clinically significant missense variants in CYP1B1 — a pathogenic mutation that disrupts the enzyme's catalytic function and is a well-established cause of primary congenital glaucoma (PCG)²² primary congenital glaucoma (PCG)
a rare inherited form of glaucoma presenting at birth or in the first year of life, characterized by elevated intraocular pressure and progressive optic nerve damage.

PCG is an autosomal recessive disease: two pathogenic CYP1B1 alleles are required for affected status. Individuals carrying a single copy of the Arg469Trp allele (heterozygous carriers) have normal vision but may pass the variant to their children.

The Mechanism

CYP1B1 is expressed in the trabecular meshwork and other anterior segment tissues during eye development. Loss of its enzymatic activity is thought to disrupt the metabolism of steroid signaling molecules critical for anterior segment morphogenesis³³ steroid signaling molecules critical for anterior segment morphogenesis
possibly including steroids involved in trabecular meshwork differentiation and aqueous humor outflow pathway development. When both copies of CYP1B1 are non-functional, the trabecular meshwork fails to develop correctly, blocking aqueous humor drainage and causing the elevated intraocular pressure that defines congenital glaucoma.

The Arg469Trp substitution sits in the heme-binding region of the protein. Unlike some CYP1B1 mutations that destabilize the protein, Jansson et al. showed the R469W holoenzyme is paradoxically stabilized⁴⁴ Jansson et al. showed the R469W holoenzyme is paradoxically stabilized
yet its catalytic activity against steroid substrates including testosterone, progesterone, and estradiol is substantially impaired, with altered metabolite profiles compared to wild-type. Mammen et al. confirmed that R469W reduces CYP1B1 activity against carcinogen substrates to only 3–12% of wild-type levels⁵⁵ 3–12% of wild-type levels
a near-complete functional knockout of enzymatic capacity.

The Evidence

CYP1B1 mutations were first established as the predominant cause of PCG in Saudi Arabia by Bejjani et al. 1998⁶⁶ Bejjani et al. 1998
establishing linkage to the GLC3A locus on chromosome 2p21 in 24 of 25 Saudi families. A follow-up study found that G61E, R469W, and D374N account for 72%, 12%, and 7% respectively of all PCG chromosomes in Saudi families⁷⁷ G61E, R469W, and D374N account for 72%, 12%, and 7% respectively of all PCG chromosomes in Saudi families
with R469W emerging as the second most common founder mutation in this population. Incomplete penetrance was documented — 40 unaffected individuals from 22 families carried identical mutations to affected siblings — suggesting a modifier locus can suppress disease expression.

In Iran, Chitsazian et al. 2007⁸⁸ Chitsazian et al. 2007
examining 104 Iranian PCG patients identified R469W as one of four mutations collectively comprising 76.2% of CYP1B1 mutated alleles in this population. Badeeb et al. 2014⁹⁹ Badeeb et al. 2014
studying 34 Saudi PCG patients found R469W homozygous in 14.8% of genetically solved cases, with severe disease phenotype; 30% of the ten most severe cases carried homozygous R469W. Rauf et al. 2016¹⁰¹⁰ Rauf et al. 2016
analyzing 23 Pakistani PCG families confirmed R469W's presence across South Asian and Middle Eastern populations.

Beyond glaucoma, CYP1B1 metabolizes 17β-estradiol to 4-hydroxyestradiol¹¹¹¹ 17β-estradiol to 4-hydroxyestradiol
a catechol estrogen metabolite that can form DNA adducts and has been implicated in estrogen-related cancer risk. Reduced CYP1B1 activity from R469W alters the balance of estrogen metabolites, though the clinical cardiovascular and cancer implications of carrier status are less well characterized than the glaucoma association.

Practical Implications

For homozygous carriers (AA genotype), PCG typically presents within the first year of life with symptoms including tearing, photophobia, blepharospasm, and cloudy corneas. Early pediatric ophthalmology evaluation is essential. Surgical treatment — goniotomy or trabeculotomy — is the mainstay of therapy and has a high success rate when performed early. Genetic confirmation allows targeted family counseling in consanguineous families.

For heterozygous carriers (one A allele), personal glaucoma risk is not elevated. However, if both parents carry a CYP1B1 pathogenic variant, each child has a 25% chance of inheriting two pathogenic copies and developing PCG.

The globally rare frequency of R469W (~0.005% overall) rises substantially in consanguineous Middle Eastern and South Asian populations where the variant originated. Genetic screening of at-risk families enables earlier diagnosis and better outcomes for affected children.

Interactions

The R469W variant occurs in the same gene as many other CYP1B1 pathogenic mutations. Compound heterozygosity — one R469W allele plus a different CYP1B1 pathogenic variant on the other chromosome — can also cause PCG and is clinically equivalent to R469W homozygosity. The most common co-occurring mutations in Middle Eastern populations are G61E (p.Gly61Glu) and D374N (p.Asp374Asn). Modifier loci elsewhere in the genome may suppress disease expression in some carriers, which explains documented incomplete penetrance in family studies.